Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study

Dao, Minh

244 - Poster Session A
Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study

Saturday, March 22, 2014: 8:25 PM

West Exhibit Hall (Tampa Convention Center)

M. D. Dao¹, E. Zsiros², R. R. Urban¹, H. J. Gray¹, H. K. Tamimi¹, B. A. Goff¹, J. L. Tanyi² and J. B. Liao³
¹University of Washington Medical Center, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³University of Washington, Seattle, WA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

244 - Poster Session A
Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study

244 - Poster Session A Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study

244 - Poster Session A
Prognostic factors for overall survival in recurrent ovarian, Fallopian tube, and peritoneal cancer patients treated with bevacizumab: a multisite study